What Is Autologous Cell Therapy? India's Complete Patient Guide | ALIV

Every day, across ALIV's Pune and Mumbai clinics, we meet patients who have exhausted what conventional medicine's standard toolkit can offer for their condition — and who are looking for something that works at a deeper biological level without the risks of foreign materials, immunosuppression, or experimental compounds of unknown origin. Autologous Cell Therapy (ACT) is ALIV's answer to that clinical need: a regenerative medicine approach that uses your own biology to support your own healing.

ALIV has been a pioneer in autologous regenerative medicine in India since 2015, and the clinical approach reflects a decade of experience applying this principle across a wide range of conditions — from joint degeneration and neurological illness to metabolic disease and reproductive challenges. This guide explains what ACT is, how it works, and how to think about it as part of a clinical management plan.

The Autologous Principle: Why "Your Own Cells" Matters

The word "autologous" means derived from the same individual — the cells used in ACT come from the patient's own body, are processed, and are returned to the same patient. This distinguishes ACT fundamentally from allogenic therapies (using donor cells), synthetic biologics, or any approach that introduces foreign biological material. The autologous nature of ACT carries a profound safety advantage: because the biological material is entirely self-derived, there is no risk of immune rejection, no donor-matching requirement, no risk of transmitting donor-derived infections, and no immunosuppression required before or after the procedure.

At ALIV, ACT involves harvesting biological material — typically from bone marrow or adipose (fat) tissue — processing it in a controlled clinical environment to concentrate the therapeutically relevant cell populations and growth factors, and then reintroducing these concentrated materials to specific target areas or systemically, depending on the clinical indication. The concentrated cells and growth factors produce their therapeutic effects through what are called paracrine mechanisms — signalling to surrounding cells and tissues to reduce inflammation, recruit the body's own repair mechanisms, and promote the regenerative processes that have been overwhelmed or suppressed by disease.

What ACT Is Designed to Do

ACT is not designed to replace damaged cells with identical functional replacements in the way that organ transplant aims to restore function. Its therapeutic action is primarily paracrine and modulatory: it delivers a concentrated payload of anti-inflammatory signals, growth factors (including PDGF, TGF-β, IGF-1, VEGF, and HGF depending on the cell source and preparation), and cell populations that communicate with the tissue environment to shift it from a chronic inflammatory, degenerative state toward a regenerative, repair-favouring state. This is a meaningful biological shift — but it is additive and supportive rather than curative. ACT is most accurately described as a powerful addition to existing care rather than a replacement for it.

The clinical goal at ALIV is meaningful improvement in quality of life, functional capacity, and symptom burden — not elimination of the underlying condition. For a patient with osteoarthritis, meaningful improvement means less pain and better joint function. For a Parkinson's patient, it may mean slower progression and better motor symptom management. For a liver patient, it may mean improved hepatic function markers and reduced fatigue. The target is always defined in consultation with the patient and family before any treatment begins. See the full clinical framework: ACT India: complete patient guide.

How is ACT different from stem cell therapy?

This is the most common point of confusion in regenerative medicine. True stem cell therapy involves undifferentiated pluripotent or multipotent stem cells that theoretically can differentiate into multiple cell types — this is a fundamentally different and more experimental approach with distinct regulatory, safety, and efficacy questions. ALIV's ACT uses differentiated or partially differentiated adult cell populations from the patient's own bone marrow or adipose tissue — these are not pluripotent stem cells, and ALIV does not position ACT as stem cell therapy. The therapeutic action is primarily paracrine rather than direct cell replacement. This distinction matters for accurate patient understanding. See: ACT vs stem cell therapy explained.

Is ACT approved by Indian regulatory authorities?

The regulatory landscape for regenerative cell therapies in India is evolving. ALIV operates within the applicable regulatory framework for autologous cell therapies and follows strict quality and safety standards in its clinical protocols. All patients receive detailed informed consent that describes the experimental and proprietary nature of ACT protocols. Patients should feel entitled to ask ALIV's clinical team directly about the regulatory context of the specific protocol being recommended for their condition — and ALIV's team is committed to full transparency in response.

Which conditions is ACT used for at ALIV?

ALIV's ACT programme addresses a range of conditions where conventional medicine has produced plateau outcomes and where regenerative signalling offers meaningful additional clinical benefit. These include: osteoarthritis and rheumatoid arthritis; neurological conditions including Parkinson's disease, Alzheimer's disease, and stroke rehabilitation; metabolic conditions including type 2 diabetes complications; liver disease; inflammatory bowel conditions including Crohn's disease; infertility and reproductive health; COPD; and restorative anti-ageing for overall vitality and tissue function. Each condition has a specific ACT protocol — the approach is individualised, not one-size-fits-all.

How long does an ACT treatment course take?

A complete ACT protocol at ALIV typically involves a series of sessions over weeks to months, depending on the condition and the clinical protocol. An individual session involves blood draw or cell harvest, processing (which takes a few hours in the ALIV laboratory), and administration — the full session duration is typically half to a full day at the clinic. Some protocols involve multiple administrations at defined intervals; others involve a primary session followed by maintenance. The specific timeline is discussed in detail at the pre-ACT clinical consultation.

What does the pre-ACT consultation involve?

The pre-ACT consultation at ALIV involves a detailed clinical history review, assessment of current medical management and medications, review of recent investigations, and a frank discussion of what ACT can realistically offer for the specific condition at the specific stage the patient is at. Patients with conditions at very advanced stages or with significant coexisting contraindications may not be appropriate candidates — the consultation identifies this clearly so patients can make fully informed decisions. Family members are welcome and often valuable participants in this conversation.